Russian oligarch Vitaly Malkin plans to sue Credit Suisse for CHF500 million ($515 million) due to losses caused by a former employee of the bank, according to a newspaper report.
This content was published on
2 minutes
SonntagsZeitung/AFP/dos
Português
pt
Credit Suisse: novas preocupações legais ligadas ao antigo banqueiro malfeitor
The SonntagsZeitung writes that Malkin is chasing the bank in connection with the shrinking of his fortune between 2007 and 2008. Malkin, a former business partner of ex-Georgian Prime Minister Bidzina Ivanishvili, also wants Credit Suisse to look in more detail into the activities of its former employee Patrice Lescaudron and to find out what happened to his money.
Lescaudron worked for Credit Suisse in Geneva, where he was responsible for handling wealthy clients from Eastern Europe. After being fired by the bank in 2015, the banker was sentenced to a five-year jail term in 2018 for fraud and forgery. He committed suicide in 2020.
Lone wolf
On Sunday, Credit Suisse told the SonntagsZeitung as well as the AFP news agency that it rejected the allegations raised by Malkin.
The bank said that not only had Lescaudron’s actions “not been damaging” to Malkin and his fortune, but various court cases had concluded that the rogue banker had acted alone and was “not helped by other [Credit Suisse] employees in his criminal activities”.
However, the fallout from the Lescaudron case is not over: in March, a court in Bermuda ruled that Ivanishvili had suffered losses of $553 million due to the banker’s placements – a verdict Credit Suisse plans to appeal. And earlier this week, Bloomberg reported that the Geneva public prosecutor had identified eight suspicious transactions between 2008 and 2014, which he believes were laundered through Credit Suisse, and which could be grounds for a legal indictment brought against the bank.
More
More
Swiss bank faces money-laundering trial over Bulgarian drug funds
This content was published on
Credit Suisse “first major Swiss bank” to be tried for money laundering as part of Bulgarian drug ring court case.
This content was published on
Swiss pharmaceutical company Novartis is buying in the United States. The biopharmaceutical company Tourmaline Bio is to be acquired for around $1.4 billion (CHF1.1 billion).
Swiss Senate rejects sanctions against Israeli settlers
This content was published on
The Swiss Senate has rejected a call for Switzerland to join the EU’s sanctions against violent Israeli settlers. The majority also did not want an end to military cooperation with Israel.
Zurich authorities want ‘no taxpayer money for terrorists’
This content was published on
Zurich cantonal parliament has voted against recognising the state of Palestine. However, it provisionally supported a motion calling for “no taxpayers' money for terrorists”.
Swiss mechanical firms were struggling before Trump
This content was published on
Swiss mechanical engineering companies are said to be one of the main victims of Donald Trump's high tariffs. However, the industry has been struggling for years.
SNB head warns of side effects of negative interest rates
This content was published on
The Swiss National Bank (SNB) takes a critical view of the reintroduction of negative interest rates. "We are aware that the negative interest rate can have undesirable side effects, for example for savers and pension funds."
Credit Suisse loses case over banker who stole from billionaire clients
This content was published on
Former Georgian prime minister Bidzina Ivanishvili has won a long-running battle with Credit Suisse to reclaim funds stolen by a former employee.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.